Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab for fulminant acne (multi-center, single-arm, exploratory)
ChiCTR2600127188Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vunakizumab in acne fulminans (AF), sponsored by West China Hospital of Sichuan University. Primary endpoints: Improvement rate of GAGS score at week 12 and Reduction rate of inflammatory lesion count at week 12. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
vunakizumab
03
Conditions
acne fulminans (AF)
Beyond the preview
Go deeper on ChiCTR2600127188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127188.